Edition:
United States

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

56.07USD
21 Jun 2017
Change (% chg)

-- (--)
Prev Close
$56.07
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,695,916
52-wk High
$77.10
52-wk Low
$46.01

Select another date:

Wed, Jun 21 2017

BRIEF-Bristol-Myers Squibb announces expiration of cash tender offer

* Bristol-Myers Squibb announces the expiration of its cash tender offer

BRIEF-Bristol-Myers Squibb to sell manufacturing facility to SK Biotek Co

* Bristol-Myers Squibb to sell manufacturing facility in swords, Ireland to SK Biotek Co., Ltd.

BRIEF-Seattle Genetics, Bristol-Myers Squibb highlight interim phase 1/2 data

* Seattle Genetics and Bristol-Myers Squibb highlight interim phase 1/2 data evaluating combination of adcetris® (brentuximab vedotin) and opdivo® (nivolumab) in relapsed hodgkin lymphoma at the international conference on malignant lymphoma

BRIEF-Bristol-Myers Squibb announces cash tender offer

* Announces cash tender offer for any and all of certain of its outstanding debt securities

BRIEF-Bristol-Myers Squibb declares quarterly dividend of $0.39/shr

* Bristol-Myers Squibb Co says declared a quarterly dividend of $0.39 per share on $.10 par value common stock of corporation Source text for Eikon: Further company coverage:

BRIEF-Bristol-Myers announces availability of Orencia subcutaneous administration option for patients above 2 yrs of age with moderately to severely active polyarticular JIA

* Bristol-Myers Squibb announces availability of new Orencia (abatacept) subcutaneous administration option for patients 2 years of age and older with moderately to severely active polyarticular Juvenile Idiopathic Arthritis (JIA) Source text for Eikon: Further company coverage:

BRIEF-Bristol-Myers Squibb announces new collaboration to evaluate combination therapy in colorectal cancer

* Bristol-Myers Squibb announces new collaboration to evaluate combination therapy in colorectal cancer

BRIEF-Novartis announces clinical collaboration with Bristol-Myers Squibb

* Novartis announces clinical collaboration with Bristol-Myers Squibb to evaluate potential treatments in metastatic colorectal cancer Source text for Eikon: Further company coverage:

BRIEF-Incyte says epacadostat, Bristol-Myers' Opdivo combo data positive in head and neck cancer patients

* Clinical trial data for combination of epacadostat and opdivo® (nivolumab) demonstrate durable clinical responses in patients with melanoma and head and neck cancer

BRIEF-European commission approves Bristol-Myers Squibb’s opdivo (nivolumab)

* European Commission approves Bristol-Myers Squibb’s opdivo (nivolumab) for previously treated locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy

Select another date:

More From Around the Web